Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia and familial hypophosphatemic rickets. The pharmaceutical is active against fibroblast growth factor 23.
|Indication||familial hypophosphatemia, familial hypophosphatemic rickets|
|Drug Class||Monoclonal antibodies: fully human, bone target|